Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation.
COPD
pharmacodynamics
pharmacokinetics
tigecycline
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
18
01
2023
revised:
31
01
2023
accepted:
01
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
We aimed to evaluate the pharmacokinetic profile of tigecycline in plasma and its penetration to sputum in moderately ill patients with an infectious acute exacerbation of chronic obstructive pulmonary disease (COPD). Eleven patients hospitalized with acute respiratory failure due to an acute COPD exacerbation with clinical evidence of an infectious cause received tigecycline 50 mg twice daily after an initial loading dose of 100 mg. Blood and sputum samples were collected at steady state after dose seven. In plasma, mean C Our findings support the clinical effectiveness of tigecycline against commonly causative bacteria in COPD exacerbations and highlight its sufficient lung penetration in pulmonary infections of moderate severity.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to evaluate the pharmacokinetic profile of tigecycline in plasma and its penetration to sputum in moderately ill patients with an infectious acute exacerbation of chronic obstructive pulmonary disease (COPD).
METHODS
METHODS
Eleven patients hospitalized with acute respiratory failure due to an acute COPD exacerbation with clinical evidence of an infectious cause received tigecycline 50 mg twice daily after an initial loading dose of 100 mg. Blood and sputum samples were collected at steady state after dose seven.
RESULTS
RESULTS
In plasma, mean C
CONCLUSIONS
CONCLUSIONS
Our findings support the clinical effectiveness of tigecycline against commonly causative bacteria in COPD exacerbations and highlight its sufficient lung penetration in pulmonary infections of moderate severity.
Identifiants
pubmed: 36830217
pii: antibiotics12020307
doi: 10.3390/antibiotics12020307
pmc: PMC9952492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2013 Nov 08;8(11):e79603
pubmed: 24282510
Lancet Infect Dis. 2011 Nov;11(11):834-44
pubmed: 21784708
Int J Antimicrob Agents. 2005 Jun;25(6):523-9
pubmed: 15885987
Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72
pubmed: 21173186
J Antimicrob Chemother. 2006 Aug;58(2):256-65
pubmed: 16816396
Int J Antimicrob Agents. 2009 Jan;33(1):58-64
pubmed: 18835762
Clin Pharmacokinet. 2011 Oct;50(10):637-64
pubmed: 21895037
Diagn Microbiol Infect Dis. 2013 Apr;75(4):331-6
pubmed: 23357291
Antimicrob Agents Chemother. 2007 Nov;51(11):4085-9
pubmed: 17846139
Clin Infect Dis. 2012 Jun;54(12):1699-709
pubmed: 22467668
Crit Care. 2014 May 05;18(3):R90
pubmed: 24887101
Curr Drug Metab. 2009 Jan;10(1):13-21
pubmed: 19149509
Int J Infect Dis. 2014 Jan;18:62-7
pubmed: 24246741
J Infect. 2009 Apr;58(4):273-84
pubmed: 19344841
Respir Med. 2019 Oct;157:1-6
pubmed: 31450162
Ther Adv Respir Dis. 2008 Apr;2(2):95-107
pubmed: 19124362
Int J Chron Obstruct Pulmon Dis. 2012;7:555-69
pubmed: 22969296
Clin Pharmacokinet. 1990 Dec;19(6):462-90
pubmed: 2292169
Intensive Care Med. 2014 Jul;40(7):1039-45
pubmed: 24871501
J Antimicrob Chemother. 2009 May;63(5):982-7
pubmed: 19279050
J Infect. 2010 Apr;60(4):306-8
pubmed: 20144899
Int J Antimicrob Agents. 2022 Jan;59(1):106487
pubmed: 34843925
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459-70
pubmed: 21958044
Antimicrob Agents Chemother. 2012 Jan;56(1):130-6
pubmed: 21968360
J Glob Antimicrob Resist. 2021 Jun;25:315-322
pubmed: 33957288
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28696233
J Antimicrob Chemother. 2009 Oct;64(4):837-9
pubmed: 19696049
ERJ Open Res. 2019 Nov 15;5(4):
pubmed: 31754621
J Antimicrob Chemother. 2019 Oct 1;74(10):2848-2864
pubmed: 31127283
New Microbiol. 2015 Apr;38(2):121-36
pubmed: 25915055
Int J Antimicrob Agents. 2009 Jul;34(1):101-2
pubmed: 19278835
J Glob Antimicrob Resist. 2021 Sep;26:1-3
pubmed: 34020074
J Antimicrob Chemother. 2011 Sep;66(9):1963-71
pubmed: 21685488